Keytruda Powder (pembrolizumab)

USES: Pembrolizumab is used to treat cancer. It works by changing how your immune system works, making it attack cancer cells. Pembrolizumab belongs to a class of drugs known as monoclonal antibodies.

Generic name: pembrolizumab
Pronunciation: (PEM-broe-LIZ-ue-mab)

The following indications are listed for Keytruda Powder:

• Adjuvant Treatment Of Melanoma
• Biliary Tract Malignancy
• Carcinoma Of Cervix
• Early-Stage Triple-Negative Breast Cancer
• Egfr Negative, Alk Negative, Non-Small Cell Lung Cancer
• Endometrial Carcinoma
• Hodgkin's Lymphoma
• Invasive Bladder Cancer
• Liver Cell Carcinoma
• Malignant Melanoma
• Malignant Mesothelioma Of Pleura
• Merkel Cell Carcinoma
• Microsatellite Instability-High Colorectal Cancer
• Microsatellite Instability-High Solid Malignant Tumor
• Mismatch Repair Deficient Endometrial Cancer
• Mismatch Repair Proficient Endometrial Cancer
• Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ
• Non-Small Cell Lung Cancer
• Pd-L1 Expressing Epithelial Ovarian Carcinoma
• Pd-L1 Expressing Fallopian Tube Carcinoma
• Pd-L1 Expressing Triple-Negative Breast Cancer
• Pd-L1 Positive Adenocarcinoma Of Gastroesophageal Junction
• Pd-L1 Positive Cervical Cancer
• Pd-L1 Positive Esophageal Carcinoma
• Pd-L1 Positive Non-Small Cell Lung Cancer
• Pd-L1 Positive Squamous Cell Carcinoma Of Esophagus
• Pd-L1 Positive Squamous Cell Carcinoma Of Head And Neck
• Pd-L1 Positive, Egfr-Negative, Alk-Negative Metastatic Non-Small Cell Lung Cancer
• Pd-L1+, Her2-Negative Gastric Or Gastroesophageal Junction Adenocarcinoma
• Pd-L1+, Her2-Positive Gastric Or Gastroesophageal Junction Adenocarcinoma
• Primary Mediastinal Large B-Cell Lymphoma
• Renal Cell Carcinoma
• Squamous Cell Carcinoma Of Head And Neck
• Squamous Cell Carcinoma Of Lung
• Squamous Cell Carcinoma Of Skin
• Transitional Cell Carcinoma Of The Urinary Tract
• Tumor Mutational Burden-High Solid Malignant Tumor

Also known as: Anemia Lymphatica, Biliary Cancer, Biliary Malignancy, Carcinoma Of Fallopian Tube W/ Pd-L1 Expression, Carcinoma Of Kidney, Cervical Carcinoma, Cervical Carcinoma Cancer, Cutaneous Neuroendocrine Carcinoma, Cutaneous Squamous Cell Carcinoma, Dmmr Cancer, Dmmr Colorectal Cancer, Dmmr Endometrial Cancer, Dmmr Solid Malignant Tumor, Early-Stage Hormone Receptor (Er/Pr)-Negative, Her2-Negative Breast Cancer, Early-Stage Hormone Receptor-Negative, Her2-Negative Breast Cancer, Early-Stage Hr-Negative, Her2-Negative Breast Cancer, Early-Stage Tnbc, Egfr-Negative, Alk Mut (-) Non-Small Cell Lung Cancer, Egfr-Negative, Alk-Negative, Nsclc, Epidermoid Carcinoma Of Lung, Epidermoid Carcinoma Of The Head And Neck, Gallbladder Or Bile Duct Cancer, Grawitz Tumor, Hepatocarcinoma, Hepatocellular Carcinoma, Hodgkin's Disease, Hormone Receptor (Hr)-Negative, Her2-Negative, Pd-L1 Expressing Breast Cancer, Hr Negative, Her2 Negative, Pd-L1 Positive Breast Cancer, Hypernephroid Carcinoma, Hypernephroma, Invasive Malignancy Of Bladder, Kidney Adenocarcinoma, Malignant Neoplasm Of Gallbladder Or Bile Ducts, Malignant Tumor Of Gallbladder Or Bile Ducts, Melanoblastoma, Melanocarcinoma, Melanoma, Melanosarcoma, Melanotic Carcinoma, Mismatch Repair Deficient Colorectal Cancer, Mismatch Repair Deficient Solid Malignant Tumor, Msi-H Cancer, Msi-H Colorectal Cancer, Msi-H Solid Malignant Tumor, Muscle Invasive Bladder Cancer, Nephroid Carcinoma, Neuroendocrine Carcinoma Of The Skin, Ovarian Epithelial Cancer With Pd-L1 Expression, Pd-L1 Expressing Epithelial Ovarian Carcer, Pd-L1 Expressing Malignant Tumor Of Fallopian Tube, Pd-L1 Expressing Non-Small Cell Lung Cancer, Pd-L1 Expressing, Egfr Mutation Negative, Alk Mutation Negative Metastatic Nsclc, Pd-L1 Ovarian Carcinoma, Pd-L1 Positive Adenocarcinoma Of Cardioesophageal Junction, Pd-L1 Positive Esophageal Squamous Cell Carcinoma, Pd-L1 Positive Metastatic Non-Small Cell Lung Cancer With No Egfr Or Alk Mutations, Pd-L1 Positive Nsclc, Pd-L1 Positive Scc Of Esophagus, Pd-L1 Positive, Egfr-Negative, Alk-Negative Nsclc, Pd-L1+ Scc Of Esophagus, Pdcd1l1 Positive Non-Small Cell Lung Cancer, Pmmr Endometrial Cancer, Programmed Cell Death 1 Ligand 1 Positive Gastroesophageal Adenocarcinoma, Programmed Cell Death 1 Ligand 1 Positive Nsclc, Programmed Death Ligand 1 Positive Adenocarcinoma Of Gastroesophageal Junction, Programmed Death Ligand 1 Positive Non-Small Cell Lung Cancer, Renal Adenocarcinoma, Renal Carcinoma, Renal Cell Adenocarcinoma, Scc Of Lung, Skin Squamous Cell Carcinoma (Scc), Solid Malignant Tumor With >=10 Mutations/Megabase (Mut/Mb), Squamous Cell Lung Carcinoma, Squamous Non-Small Cell Lung Cancer, Squamous Nsclc, Tmb-H Solid Malignant Tumor, Trabecular Cell Carcinoma Of Skin, Urothelial Carcinoma.

No ICD codes are available for this drug.